About
Development of therapies for Neurofibromatosis 1
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (14)
Amy Paller
Amy Paller, M.D., Ph.D.
NFlection Therapeutics
team_member
Barbara Gilchrest
Barbara Gilchrest, M.D.
NFlection Therapeutics
team_member
Chief Development Officer
Christopher Powala
NFlection Therapeutics
team_member
Chief Executive Officer
William Hodder
NFlection Therapeutics
team_member
Chief Financial Officer
Diane Marcou
NFlection Therapeutics
team_member
Chief Medical Officer
Guy Webster
NFlection Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
247
By Phase
PHASE2: 3
By Status
COMPLETED: 2WITHDRAWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05195762Collaborator
12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi
PHASE2Withdrawn
Started: Jun 30, 2023 · Completed: Dec 31, 2024
NCT05005845Lead Sponsor
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
PHASE2Completed
199 participants
Started: Sep 20, 2021 · Completed: Oct 4, 2023
NCT04435665Lead Sponsor
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
PHASE2Completed
48 participants
Started: Aug 21, 2020 · Completed: Apr 14, 2021
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...